source
- Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugsThe lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “…BioPharma Dive · 10d ago↗ source
- Opinion: Pete Hegseth, ‘The Odyssey,’ and the testosterone mythThe poet didn’t say “sing to me, Muse, of a man with optimized endocrine panels," writes urologist Elizabeth Dray.STAT · 10d ago↗ source
- Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.BioPharma Dive